← All trials
NCT00056329
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2002
- Primary completion
- May 1, 2012
- Completion date
- May 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- State of New YorkLead sponsor
- Georgetown UniversityStudy director
- National Institute on Aging (NIA)Collaborator
- National Center for Complementary and Integrative Health (NCCIH)Collaborator
- National Institutes of Health (NIH)Collaborator
- State of New YorkReponsible party - principal investigator
- State of New YorkOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.